Colorectal Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with cancer in the lower or middle part of the rectum (confirmed by laboratory testing of tissue), at stage II or stage III
- People who are planned to receive pre-surgery treatment, such as a combination of radiation and chemotherapy, chemotherapy alone, or radiation alone (certain chemotherapy combinations given before the main treatment are also allowed)
- People who have signed the official consent form agreeing to take part in the study
- People aged 18 or older, male or female
- People who are willing and able to use appropriate contraception from the start of the trial until at least 8 weeks after the last round of treatment — this applies to men and to women who have not yet gone through menopause
Who may not be able to join:
- People who have taken antibiotics at the time of, or within the month before, the stool sample is collected
- People who currently have a stoma (a surgically created opening in the abdomen for waste to leave the body)
- People who have already received treatment for rectal cancer previously
- People who are not registered with the French social protection (healthcare) system
- People where psychological, family, social, or geographical reasons may make it difficult to follow the treatment plan as required
- People who are under a legal guardianship or curatorship arrangement
- People who have had radiation therapy to the pelvis area within the year before joining the trial
- People who have had another cancer diagnosed within the last 5 years (exceptions may apply for certain early-stage cervical or skin cancers that have been fully treated — confirm with trial site)
- People who are pregnant or currently breastfeeding
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Philippe ROUANET, MD, Institut régional du cancer de Montpellier
Phone: 0467612446
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
The ratio between the proportions of poor response to neoadjuvant treatment in populations so-called "exposed" (patients colonized by bacteria producing toxins (cyclomodulin) and unexposed (patients not colonized by bacteria producing toxins)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.